APO Research
Talk to an analyst

APO RESEARCH · REPORT

Postmenopausal Vaginal Atrophy Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Postmenopausal Vaginal Atrophy Drugs Industry Growth and Trends Forecast to 2032

22 December 202593 pages

Choose your research edition.

Industry ResearchPostmenopausal Vaginal Atrophy Drugs Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Postmenopausal Vaginal Atrophy Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Postmenopausal Vaginal Atrophy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Postmenopausal Vaginal Atrophy Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Postmenopausal Vaginal Atrophy Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Postmenopausal Vaginal Atrophy Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Postmenopausal Vaginal Atrophy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Postmenopausal Vaginal Atrophy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Postmenopausal Vaginal Atrophy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Postmenopausal Vaginal Atrophy Drugs include Teva Pharmaceutical Industries, Novo Nordisk, Pfizer, Millicent Pharma, Endoceutics, Duchesnay USA and Aspen Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Postmenopausal Vaginal Atrophy Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Postmenopausal Vaginal Atrophy Drugs market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Postmenopausal Vaginal Atrophy Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Postmenopausal Vaginal Atrophy Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Postmenopausal Vaginal Atrophy Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Postmenopausal Vaginal Atrophy Drugs Market by Company

Teva Pharmaceutical Industries

Novo Nordisk

Pfizer

Millicent Pharma

Endoceutics

Duchesnay USA

Aspen Pharma

Postmenopausal Vaginal Atrophy Drugs Segment by Type

Tablets

Suppositories

Creams

Rings

Postmenopausal Vaginal Atrophy Drugs Segment by Application

Offline Stores

Online Stores

Postmenopausal Vaginal Atrophy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Postmenopausal Vaginal Atrophy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Postmenopausal Vaginal Atrophy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Postmenopausal Vaginal Atrophy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Postmenopausal Vaginal Atrophy Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Postmenopausal Vaginal Atrophy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Tablets Table 2. Major Company of Suppositories Table 3. Major Company of Creams Table 4. Major Company of Rings Table 5. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 6. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 7. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2021-2026) Table 8. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 9. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2021-2026) Table 10. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2021-2026) & (US$/unit) Table 11. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2027-2032) & (k units) Table 12. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type (2027-2032) Table 13. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2027-2032) & (US$ Million) Table 14. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type (2027-2032) Table 15. Global Postmenopausal Vaginal Atrophy Drugs Price by Type (2027-2032) & (US$/unit) Table 16. North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 17. North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 19. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 21. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 23. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (k units) Table 25. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Type (2021-2026) & (US$ Million) Table 26. Postmenopausal Vaginal Atrophy Drugs Industry Trends Table 27. Postmenopausal Vaginal Atrophy Drugs Industry Drivers Table 28. Postmenopausal Vaginal Atrophy Drugs Industry Opportunities and Challenges Table 29. Postmenopausal Vaginal Atrophy Drugs Industry Restraints Table 30. Global Postmenopausal Vaginal Atrophy Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 31. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Company (2021-2026) Table 32. Global Postmenopausal Vaginal Atrophy Drugs Sales by Company (2021-2026) & (k units) Table 33. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Company (2021-2026) Table 34. Global Postmenopausal Vaginal Atrophy Drugs Market Price by Company (2021-2026) & (US$/unit) Table 35. Global Postmenopausal Vaginal Atrophy Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 36. Global Postmenopausal Vaginal Atrophy Drugs Major Company Production Sites and Headquarters Table 37. Global Postmenopausal Vaginal Atrophy Drugs Company, Product Type & Application Table 38. Global Postmenopausal Vaginal Atrophy Drugs Company Establishment Date Table 39. Global Company Market Concentration Ratio (CR5 and HHI) Table 40. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 41. Global Postmenopausal Vaginal Atrophy Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 42. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2021-2026) & (k units) Table 43. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Region (2021-2026) Table 44. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2021-2026) & (US$ Million) Table 45. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Region (2021-2026) Table 46. Global Postmenopausal Vaginal Atrophy Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 47. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2027-2032) & (k units) Table 48. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Region (2027-2032) Table 49. Global Postmenopausal Vaginal Atrophy Drugs Sales by Region (2027-2032) & (US$ Million) Table 50. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Region (2027-2032) Table 51. Global Postmenopausal Vaginal Atrophy Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 52. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 53. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 54. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2021-2026) Table 55. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 56. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2021-2026) Table 57. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2021-2026) & (US$/unit) Table 58. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2027-2032) & (k units) Table 59. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application (2027-2032) Table 60. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2027-2032) & (US$ Million) Table 61. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application (2027-2032) Table 62. Global Postmenopausal Vaginal Atrophy Drugs Price by Application (2027-2032) & (US$/unit) Table 63. North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 64. North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 66. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 68. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 70. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (k units) Table 72. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Application (2021-2026) & (US$ Million) Table 73. Teva Pharmaceutical Industries Company Information Table 74. Teva Pharmaceutical Industries Business Overview Table 75. Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 77. Teva Pharmaceutical Industries Recent Development Table 78. Novo Nordisk Company Information Table 79. Novo Nordisk Business Overview Table 80. Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 82. Novo Nordisk Recent Development Table 83. Pfizer Company Information Table 84. Pfizer Business Overview Table 85. Pfizer Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Pfizer Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 87. Pfizer Recent Development Table 88. Millicent Pharma Company Information Table 89. Millicent Pharma Business Overview Table 90. Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 92. Millicent Pharma Recent Development Table 93. Endoceutics Company Information Table 94. Endoceutics Business Overview Table 95. Endoceutics Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Endoceutics Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 97. Endoceutics Recent Development Table 98. Duchesnay USA Company Information Table 99. Duchesnay USA Business Overview Table 100. Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 102. Duchesnay USA Recent Development Table 103. Aspen Pharma Company Information Table 104. Aspen Pharma Business Overview Table 105. Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio Table 107. Aspen Pharma Recent Development Table 108. North America Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 109. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 110. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2021-2026) Table 111. North America Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2027-2032) & (k units) Table 112. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Country (2027-2032) Table 113. North America Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 114. North America Postmenopausal Vaginal Atrophy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 115. North America Postmenopausal Vaginal Atrophy Drugs Market Share by Country (2021-2026) Table 116. North America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 117. North America Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Country (2027-2032) Table 118. Europe Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 119. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 120. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2021-2026) Table 121. Europe Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2027-2032) & (k units) Table 122. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Country (2027-2032) Table 123. Europe Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 125. Europe Postmenopausal Vaginal Atrophy Drugs Market Share by Country (2021-2026) Table 126. Europe Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. Europe Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Country (2027-2032) Table 128. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 129. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 130. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2021-2026) Table 131. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2027-2032) & (k units) Table 132. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Country (2027-2032) Table 133. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 135. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Share by Country (2021-2026) Table 136. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Country (2027-2032) Table 138. Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 139. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 140. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2021-2026) Table 141. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2027-2032) & (k units) Table 142. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Country (2027-2032) Table 143. Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Latin America Postmenopausal Vaginal Atrophy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 145. Latin America Postmenopausal Vaginal Atrophy Drugs Market Share by Country (2021-2026) Table 146. Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Latin America Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Country (2027-2032) Table 148. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 149. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026) & (k units) Table 150. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2021-2026) Table 151. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2027-2032) & (k units) Table 152. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Country (2027-2032) Table 153. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 155. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Share by Country (2021-2026) Table 156. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Share Forecast by Country (2027-2032) Table 158. Key Raw Materials Table 159. Raw Materials Key Suppliers Table 160. Postmenopausal Vaginal Atrophy Drugs Distributors List Table 161. Postmenopausal Vaginal Atrophy Drugs Customers List Table 162. Research Programs/Design for This Report Table 163. Authors List of This Report Table 164. Secondary Sources Table 165. Primary Sources List of Figures Figure 1. Postmenopausal Vaginal Atrophy Drugs Image Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Postmenopausal Vaginal Atrophy Drugs Sales (2021-2032) & (k units) Figure 5. Tablets Image Figure 6. Global Tablets Sales YoY Growth (2021-2032) & (k units) Figure 7. Suppositories Image Figure 8. Global Suppositories Sales YoY Growth (2021-2032) & (k units) Figure 9. Creams Image Figure 10. Global Creams Sales YoY Growth (2021-2032) & (k units) Figure 11. Rings Image Figure 12. Global Rings Sales YoY Growth (2021-2032) & (k units) Figure 13. Global Postmenopausal Vaginal Atrophy Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 14. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Type 2025 VS 2032 Figure 15. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type in 2025 Figure 16. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type in 2025 Figure 17. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type in 2025 Figure 19. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type in 2025 Figure 21. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type in 2025 Figure 23. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Type in 2025 Figure 24. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Type in 2025 Figure 25. Global Top 5 and 10 Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue in 2025 Figure 26. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Offline Stores Image Figure 28. Global Offline Stores Sales YoY Growth (2021-2032) & (k units) Figure 29. Online Stores Image Figure 30. Global Online Stores Sales YoY Growth (2021-2032) & (k units) Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Application 2025 VS 2032 Figure 33. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application in 2025 Figure 34. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application in 2025 Figure 35. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application in 2025 Figure 39. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share in Value by Application in 2025 Figure 43. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 44. North America Postmenopausal Vaginal Atrophy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Postmenopausal Vaginal Atrophy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. Europe Postmenopausal Vaginal Atrophy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Postmenopausal Vaginal Atrophy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Postmenopausal Vaginal Atrophy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Postmenopausal Vaginal Atrophy Drugs Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Postmenopausal Vaginal Atrophy Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Tablets
  • Suppositories
  • Creams
  • Rings
Applications
  • Offline Stores
  • Online Stores
Companies covered
  • Teva Pharmaceutical Industries
  • Novo Nordisk
  • Pfizer
  • Millicent Pharma
  • Endoceutics
  • Duchesnay USA
  • Aspen Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Postmenopausal Vaginal Atrophy Drugs Market by Type
  6. 1.3.1 Tablets
  7. 1.3.2 Suppositories
  8. 1.3.3 Creams
  9. 1.3.4 Rings
  10. 1.4 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type
  11. 1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Overview by Type (2021-2032)
  12. 1.4.2 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Size Review by Type (2021-2026)
  13. 1.4.3 Global Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Type (2027-2032)
  14. 1.5 Key Regions Market Size by Type
  15. 1.5.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.3 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.4 South America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2021-2026)
  19. 1.5.5 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Postmenopausal Vaginal Atrophy Drugs Industry Trends
  2. 2.2 Postmenopausal Vaginal Atrophy Drugs Industry Drivers
  3. 2.3 Postmenopausal Vaginal Atrophy Drugs Industry Opportunities and Challenges
  4. 2.4 Postmenopausal Vaginal Atrophy Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Postmenopausal Vaginal Atrophy Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Postmenopausal Vaginal Atrophy Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Postmenopausal Vaginal Atrophy Drugs Price (2021-2026)
  4. 3.4 Global Postmenopausal Vaginal Atrophy Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Postmenopausal Vaginal Atrophy Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Postmenopausal Vaginal Atrophy Drugs Company, Product Type & Application
  7. 3.7 Global Postmenopausal Vaginal Atrophy Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Postmenopausal Vaginal Atrophy Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Postmenopausal Vaginal Atrophy Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Postmenopausal Vaginal Atrophy Drugs Tier 1, Tier 2, and Tier 3
4 Postmenopausal Vaginal Atrophy Drugs Regional Status and Outlook
  1. 4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Size by Region
  3. 4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Postmenopausal Vaginal Atrophy Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Postmenopausal Vaginal Atrophy Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Postmenopausal Vaginal Atrophy Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Postmenopausal Vaginal Atrophy Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Postmenopausal Vaginal Atrophy Drugs by Application
  1. 5.1 Postmenopausal Vaginal Atrophy Drugs Market by Application
  2. 5.1.1 Offline Stores
  3. 5.1.2 Online Stores
  4. 5.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application
  5. 5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva Pharmaceutical Industries
  2. 6.1.1 Teva Pharmaceutical Industries Company Information
  3. 6.1.2 Teva Pharmaceutical Industries Business Overview
  4. 6.1.3 Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Industries Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 6.2 Novo Nordisk
  8. 6.2.1 Novo Nordisk Company Information
  9. 6.2.2 Novo Nordisk Business Overview
  10. 6.2.3 Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novo Nordisk Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  12. 6.2.5 Novo Nordisk Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 Millicent Pharma
  20. 6.4.1 Millicent Pharma Company Information
  21. 6.4.2 Millicent Pharma Business Overview
  22. 6.4.3 Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Millicent Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  24. 6.4.5 Millicent Pharma Recent Developments
  25. 6.5 Endoceutics
  26. 6.5.1 Endoceutics Company Information
  27. 6.5.2 Endoceutics Business Overview
  28. 6.5.3 Endoceutics Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Endoceutics Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  30. 6.5.5 Endoceutics Recent Developments
  31. 6.6 Duchesnay USA
  32. 6.6.1 Duchesnay USA Company Information
  33. 6.6.2 Duchesnay USA Business Overview
  34. 6.6.3 Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Duchesnay USA Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  36. 6.6.5 Duchesnay USA Recent Developments
  37. 6.7 Aspen Pharma
  38. 6.7.1 Aspen Pharma Company Information
  39. 6.7.2 Aspen Pharma Business Overview
  40. 6.7.3 Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Aspen Pharma Postmenopausal Vaginal Atrophy Drugs Product Portfolio
  42. 6.7.5 Aspen Pharma Recent Developments
7 North America by Country
  1. 7.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country
  2. 7.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Postmenopausal Vaginal Atrophy Drugs Market Size by Country
  6. 7.2.1 North America Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Postmenopausal Vaginal Atrophy Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
  2. 8.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Country
  6. 8.2.1 Europe Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Postmenopausal Vaginal Atrophy Drugs Sales by Country
  2. 10.1.1 South America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Postmenopausal Vaginal Atrophy Drugs Market Size by Country
  6. 10.2.1 South America Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Postmenopausal Vaginal Atrophy Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Postmenopausal Vaginal Atrophy Drugs Value Chain Analysis
  2. 12.1.1 Postmenopausal Vaginal Atrophy Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Postmenopausal Vaginal Atrophy Drugs Production Mode & Process
  7. 12.2 Postmenopausal Vaginal Atrophy Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Postmenopausal Vaginal Atrophy Drugs Distributors
  10. 12.2.3 Postmenopausal Vaginal Atrophy Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst